Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 5, 2016, Pages 953-963

  Albanez S ^a   Ogiwara, K ^a   Michels, A ^a   Hopman, W ^a   Grabell, J ^a   James, P ^a   Lillicrap, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

ABO blood group system; Aging; Metabolic clearance rate; Secretion; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD GROUP A ANTIGEN; VON WILLEBRAND FACTOR; F8 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BLOOD GROUP ABO SYSTEM; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN SECRETION; BLOOD GROUP TYPING; GENOTYPE; MIDDLE AGED; VERY ELDERLY;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; AGED, 80 AND OVER; AGING; BLOOD GROUPING AND CROSSMATCHING; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FACTOR VIII; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 84971668087     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13294     Document Type: Article

References (54)

1. Lenting PJ, Christophe OD, Denis C. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125: 2019-28.
2. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-93.
3. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-59.
4. Frankel DS, Meigs JB, Massaro JM, Wilson PWF, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring Study. Circulation 2008; 118: 2533-9.
5. Robertson J, Lillicrap D, James PD. Von Willebrand disease. Pediatr Clin North Am 2008; 55: 377-92.
6. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46: 1836-44.
7. Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting PJ, Rapson D, Lillicrap D, James P. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost 2008; 6: 90-6.
8. Coppola R, Mari D, Lattuada A, Franceschi C. Von Willebrand factor in Italian centenarians. Haematologica 2003; 88: 39-43.
9. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-31.
10. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
11. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
12. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113: 5049-57.
13. Zhang H, Mooney CJ, Reilly MP. ABO blood groups and cardiovascular diseases. Int J Vasc Med 2012; 2012: 1-11.
14. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128: 100-7.
15. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-9.
16. Sanders Y, Giezenaar MA, van Laros-Gorkom B, Meijer K, van der Bom J, Cnossen M, Nijziel M, Ypma P, Fijnvandraat K, Eikenboom J, Mauser-Bunschoten E, Leebeek F. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12: 1066-1075.
17. Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia 2015; 21: 636-41.
18. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006; 60: 144-51.
19. Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008; 43: 66-73.
20. Tofler GH, Massaro J, Levy D, Mittleman M, Sutherland P, Lipinska I, Muller JE, D'Agostino RB. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 2005; 96: 1280-3.
21. Matsui T, Fujimura Y, Nishida S, Titani K. Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. Blood 1993; 82: 663-8.
22. Hironaka T, Furukawa K, Esmon PC, Fournel MA, Sawada S, Kato M, Minaga T, Kobata A. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
23. Samai A, Monlezun D, Shaban A, George A, Dowell L, Kruse-Jarres R, Schluter L, El Khoury R, Martin-Schild S. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. Stroke 2014; 45: 2789-91.
24. Lippi G, Franchini M, Salvagno GL, Montagnana M, Poli G, Guidi GC. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. J Thromb Thrombolysis 2008; 26: 150-3.
25. Smith NL, Chen M-H, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Lleal M, Bis JC, de Maat MPM, Rumley A, Kong X, Yang Q, Williams FMK, Vitart V, Campbell H, Mälarstig A, Wiggins KL, Van Duijn CM, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-92.
26. van Mourik J, Boertjes R, Huisveld I, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
27. Borchiellini A, Fijnvandraat K, ten Cate J, Pajkrt D, van Deventer S, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik J. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
28. Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, Taylor TE, Molyneux ME, Kain KC. Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS ONE 2010; 5: e15291.
29. van Mourik J, de Romani Wit T. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost 2001; 86: 164-171.
30. Verrotti A, Greco R, Basciani F, Morgese G, Chiarelli F. von Willebrand Factor and its Propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res 2003; 53: 382-6.
31. Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, Ohishi K, Maruyama K, Imai H, Mizutani H, Nobori T. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012; 129: 598-602.
32. Ito-Habe N, Wada H, Matsumoto T, Ohishi K, Toyoda H, Ishikawa E, Nomura S, Komada Y, Ito M, Nobori T, Katayama N. Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. Int J Hematol 2011; 93: 47-52.
33. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-51.
34. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111: 4979-85.
35. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121: 2336-9.
36. Casonato A, Gallinaro L, Cattini MG, Sartorello F, Pontara E, Padrini R, Bertomoro A, Daidone V, Pagnan A. Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. Transl Res 2010; 155: 200-8.
37. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.
38. Nossent A, van Marion V, van Tilburg N, Rosendaal F, Bertina R, van Mourik J, Eikenboom H. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4: 2556-62.
39. McGrath R, van den Biggelaar M, Byrne B, O'Sullivan J, Rawley O, O'Kennedy R, Voorberg J, Preston R, O'Donnell J. Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 2013; 122: 4107-10.
40. Brown S, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 2002; 87: 990-6.
41. Akin M, Balkan C, Karapinar DY, Kavakli K. The influence of the ABO blood type on the distribution of von Willebrand factor in healthy children with no bleeding symptoms. Clin Appl Thromb Hemost 2012; 18: 316-9.
42. Klarmann D, Eggert C, Geisen C, Becker S, Seifried E, Klingebiel T, Kreuz W. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion 2010; 50: 1571-80.
43. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JWC. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand Disorder. Am J Clin Pathol 2005; 124: 910-7.
44. Vischer UM, Herrmann FR, Peyrard T, Nzietchueng R, Benetos A. Plasma von Willebrand factor and arterial aging. J Thromb Haemost 2005; 3: 794-5.
45. O'Donnell J, Boulton F, Manning R, Laffan M. Amount of H antigen expressed on circulating von Willebrand Factor is modified by ABO Blood Group Genotype and is a major determinant of plasma von Willebrand Factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-41.
46. Morelli VM, de Visser MCH, van Tilburg NH, Vos HL, Eikenboom JCJ, Rosendaal FR, Bertina RM. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97: 534-41.
47. Groeneveld DJ, van Bekkum T, Cheung KL, Dirven RJ, Castaman G, Reitsma PH, van Vlijmen B, Eikenboom J. No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance. J Thromb Haemost 2015; 13: 592-600.
48. Nosaka M, Ishida Y, Tanaka A, Hayashi T, Miyashita T, Kaminaka C, Eisenmenger W, Furukawa F, Kimura A. Aberrant expression of histo-blood group A type 3 antigens in vascular endothelial cells in inflammatory sites. J Histochem Cytochem 2008; 56: 223-31.
49. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 2010; 37: 540-7.
50. Desch KC, Ozel AB, Siemieniak D, Li JZ, Ginsburg D. Linkage and association analysis of von Willebrand factor propeptide levels provides mechanistic insight into the genetic control of plasma von Willebrand factor levels. Abstract presented at the 63rd Annual Meeting of the American Society of Human Genetics (2013) in Boston, MA, USA.
51. Rizzo C, Caruso C, Vasto S. Possible role of ABO system in age-related diseases and longevity: a narrative review. Immun Ageing 2014; 11: 16-23.
52. Franchini M, Bonfanti C. Evolutionary aspects of ABO blood group in humans. Clin Chim Acta 2015; 444: 66-71.
53. Páramo J, Beloqui O, Colina I, Diez J, Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 2005; 3: 662-4.
54. Gong P, Luo S-H, Li X-L, Guo Y-L, Zhu C-G, Xu R-X, Li S, Dong Q, Liu G, Chen J, Zeng R-X, Li J-J. Relation of ABO blood groups to the severity of coronary atherosclerosis: an Gensini score assessment. Atherosclerosis 2014; 237: 748-53.